Paclitaxel

For research use only. Not for use in humans.

目录号:S1150 别名: NSC 125973, PTX, Taxol, Onxal

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 749.07 现货
RMB 571.49 现货
RMB 2235.46 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Paclitaxel发表文献157篇:

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

产品描述 Paclitaxel是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。
特性 Paclitaxel 是有丝分裂抑制剂。
靶点
Microtubule (human endothelial cells) [1]
0.1 pM
体外研究

Paclitaxel在104到 105倍更高浓度时,抑制非内皮性人类细胞,IC50 为1 nM -10 nM。Paclitaxel选择性抑制细胞增殖,具有种属特异性,在Paclitaxel极低浓度时,小鼠内皮细胞对 Paclitaxel不敏感。 极低浓度Paclitaxel抑制 人类内皮细胞,但是不影响细胞微管结构,且处理的细胞在 G2/M 期没有出现细胞周期停滞和凋亡,说明这是一种新型尚未查明的作用机制。在体外血管生成实验中,在三维纤维蛋白基质中,极低浓度Paclitaxel阻断人类内皮细胞形成芽管。[1] 在SMF存在时, Paclitaxel 作用于 K562 细胞的有效浓度从50 ng/ml降低到 10 ng/ml。在有或无SMF时,Paclitaxel 使K562 细胞周期停滞与DNA损伤相关。[2] Paclitaxel单独处理四种细胞系,包括A549 细胞,H358, H1395 细胞和H1666 细胞,抑制CDK1,这种作用存在时间依赖性。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zaR2lEPTB;MD6wNFAzQDdizszN MkKzV2FPT0WU
LC-2-ad NHjxO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXWTWM2OD1yLkCwNFMyPyEQvF2= NXGyfG55W0GQR1XS
RL95-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\ZTWM2OD1yLkCwNFY3QCEQvF2= MUXTRW5ITVJ?
MZ1-PC M1TLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[5VGlEPTB;MD6wNFA4OjlizszN NXLQc2ExW0GQR1XS
TE-8 NYiwUJVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP3TWM2OD1yLkCwNVE4KM7:TR?= M1jpR3NCVkeHUh?=
SW954 NXLmO2hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XuUmlEPTB;MD6wNFEyQSEQvF2= NV\obY5bW0GQR1XS
TE-11 NYnzdWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTnVpZpUUN3ME2wMlAxOTJ|IN88US=> MYfTRW5ITVJ?
PSN1 NXTkd|lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMECxN{DPxE1? NF7T[5ZUSU6JRWK=
MOLT-4 NH\pPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fzNWlEPTB;MD6wNFE1QSEQvF2= NFfVSJpUSU6JRWK=
697 M1\vdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W1fmlEPTB;MD6wNFE2KM7:TR?= M{HGS3NCVkeHUh?=
ETK-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfpTWM2OD1yLkCwNVUzKM7:TR?= MVrTRW5ITVJ?
TE-10 NVnrd|hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvZTY5wUUN3ME2wMlAxOTV2IN88US=> NF;P[plUSU6JRWK=
HUTU-80 NXf3dnU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHiWVlxUUN3ME2wMlAxOTZ6IN88US=> MojxV2FPT0WU
NTERA-S-cl-D1 NEDjPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC4TWM2OD1yLkCwNlA6KM7:TR?= NVvEdm5YW0GQR1XS
MFH-ino NV;lfop2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnWVVJSUUN3ME2wMlAxOjZ6IN88US=> MWjTRW5ITVJ?
IA-LM MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMECyPEDPxE1? MW\TRW5ITVJ?
MC116 NWHjOHRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPNT4o3UUN3ME2wMlAxOjh7IN88US=> MYnTRW5ITVJ?
RKO MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfUfm9KSzVyPUCuNFAzQThizszN M2DjN3NCVkeHUh?=
MRK-nu-1 NHv2OWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLyTWM2OD1yLkCwNlk6KM7:TR?= NVfYPYF5W0GQR1XS
VA-ES-BJ MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMECzJO69VQ>? M{HRbXNCVkeHUh?=
KALS-1 M{P0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX0[mxKSzVyPUCuNFA{ODhizszN MVLTRW5ITVJ?
BB30-HNC NGXKWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK0coJKSzVyPUCuNFA{OTRizszN MYDTRW5ITVJ?
ACN M3rFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMECzNVYh|ryP MnvlV2FPT0WU
TE-9 NGLJUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jNR2lEPTB;MD6wNFMzPiEQvF2= MYXTRW5ITVJ?
SIG-M5 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXEWo9KSzVyPUCuNFA{OjdizszN NVnBVo4xW0GQR1XS
no-10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P4N2lEPTB;MD6wNFM3OiEQvF2= NHrIbmlUSU6JRWK=
EW-1 NGWxNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUezUpRDUUN3ME2wMlAxOzdzIN88US=> MkLUV2FPT0WU
SK-LMS-1 NYGyRpEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEC0NFEh|ryP NWPtRlNKW0GQR1XS
GT3TKB M37RU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPqVop2UUN3ME2wMlAxPDN2IN88US=> MmPCV2FPT0WU
ES4 NX\rT3puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBTWM2OD1yLkCwOFQ6KM7:TR?= M{WwZ3NCVkeHUh?=
IMR-5 NUDHdHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37Md2lEPTB;MD6wNFQ2KM7:TR?= NELHOGpUSU6JRWK=
NCI-H1648 NGf0dWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEC0Olkh|ryP NFvr[JBUSU6JRWK=
MV-4-11 M1LXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFftdpdKSzVyPUCuNFA1PzVizszN NEP6U|FUSU6JRWK=
SK-UT-1 M1vFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PKNGlEPTB;MD6wNFQ5KM7:TR?= NHm0VmNUSU6JRWK=
NB13 NVywR2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnxfJJKSzVyPUCuNFA1QTFizszN M{LuNHNCVkeHUh?=
DJM-1 M{POT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rQSWlEPTB;MD6wNFU{KM7:TR?= M3;kdnNCVkeHUh?=
ES8 M2e2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnewTWM2OD1yLkCwOVM5KM7:TR?= M3;NOXNCVkeHUh?=
TE-6 M2DMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEC1O{DPxE1? NHrhZnFUSU6JRWK=
KS-1 NXroZWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLKTWM2OD1yLkCwOVgzKM7:TR?= NVLTcG55W0GQR1XS
TE-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XEdmlEPTB;MD6wNFYxPiEQvF2= MYrTRW5ITVJ?
ATN-1 NULBTmVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEC2NFkh|ryP M374R3NCVkeHUh?=
A4-Fuk M1;mO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfxXVBTUUN3ME2wMlAxPjFzIN88US=> MlP1V2FPT0WU
ALL-PO M17kbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMEC2N{DPxE1? MnTyV2FPT0WU
BE-13 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XJOmlEPTB;MD6wNFY{PiEQvF2= MoXqV2FPT0WU
KM12 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUmzRlBsUUN3ME2wMlAxPjN5IN88US=> NH;jOGJUSU6JRWK=
NOS-1 NFXReG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofPTWM2OD1yLkCwOlUh|ryP NUDQNpFKW0GQR1XS
SW962 NF;4eWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMEC2OlIh|ryP NW\ob2tyW0GQR1XS
OCUB-M NUHRe2J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMEC2OlIh|ryP M2fmWHNCVkeHUh?=
NCI-H510A M{fKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvuTWM2OD1yLkCwOlY2KM7:TR?= MUHTRW5ITVJ?
EW-16 M1Hv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\wcGxLUUN3ME2wMlAxPjl2IN88US=> M1TTOHNCVkeHUh?=
KGN NXu0UmFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnQcpEyUUN3ME2wMlAxPzF{IN88US=> NEHsPFhUSU6JRWK=
LS-411N M1XIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC2OoZKSzVyPUCuNFA4OTdizszN M3zmfnNCVkeHUh?=
Becker NYP0dm5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMEC3NkDPxE1? NEPUOXFUSU6JRWK=
HC-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XBeGlEPTB;MD6wNFczOSEQvF2= M{TUUnNCVkeHUh?=
CESS NGDxO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H1VWlEPTB;MD6wNFc{PyEQvF2= NHnG[lZUSU6JRWK=
KURAMOCHI NYjWXZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEC3OFgh|ryP M2jlW3NCVkeHUh?=
TGBC24TKB NYLET5BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm5TWM2OD1yLkCwO|UzKM7:TR?= NUXDUIx{W0GQR1XS
SW982 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPkTW9KSzVyPUCuNFA4PjZizszN NVLSO2ZUW0GQR1XS
HCE-4 M3zUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHITWM2OD1yLkCwO|Y4KM7:TR?= MmC0V2FPT0WU
LOUCY NHzWZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjmTWM2OD1yLkCwO|c2KM7:TR?= NIf5RopUSU6JRWK=
8-MG-BA MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7GVWdtUUN3ME2wMlAxPzl4IN88US=> NHjw[GZUSU6JRWK=
HT-144 MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDiR45KSzVyPUCuNFA5KM7:TR?= MYnTRW5ITVJ?
LXF-289 NFfxOIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTPeJNKUUN3ME2wMlAxQDF6IN88US=> M{HhWXNCVkeHUh?=
RS4-11 NX;EOZA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXToOZl1UUN3ME2wMlAxQDN4IN88US=> MlXHV2FPT0WU
DEL NGHocZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nkU2lEPTB;MD6wNFg1PSEQvF2= NF;M[mpUSU6JRWK=
OCI-AML2 M37i[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEC4OVIh|ryP NH[4UWpUSU6JRWK=
CCRF-CEM NX;jcYs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn34TWM2OD1yLkCwPFcyKM7:TR?= NHjsS4pUSU6JRWK=
A388 NX\sV4o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED4V5ZKSzVyPUCuNFA5PzRizszN Ml\aV2FPT0WU
KNS-42 MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTyTWM2OD1yLkCwPFkyKM7:TR?= MmW3V2FPT0WU
OVCAR-4 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjTTWM2OD1yLkCwPVA1KM7:TR?= Mme0V2FPT0WU
NCI-H1355 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfUTWM2OD1yLkCwPVE1KM7:TR?= NYPDN|NuW0GQR1XS
BL-70 NHzu[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDhOWJKSzVyPUCuNFA6OyEQvF2= MYXTRW5ITVJ?
BL-41 NF;5fmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEC5N|Qh|ryP MnLEV2FPT0WU
A101D NXvTO2JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm5TWM2OD1yLkCwPVYh|ryP MULTRW5ITVJ?
HL-60 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DEWmlEPTB;MD6wNFk3PiEQvF2= Mom5V2FPT0WU
COR-L279 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO1UlNKSzVyPUCuNFA6QTlizszN NUK4OZFLW0GQR1XS
NCI-SNU-16 NVK1N2NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:zd2lEPTB;MD6wNVAxQCEQvF2= M1rieXNCVkeHUh?=
Calu-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPDVlNKSzVyPUCuNFExOTJizszN MUHTRW5ITVJ?
SR NXzteWFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMEGwNlYh|ryP MVPTRW5ITVJ?
QIMR-WIL NXLUcXFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXORYtKSzVyPUCuNFExOzNizszN M2eyVnNCVkeHUh?=
LB647-SCLC NEnKSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDxTWM2OD1yLkCxNFUyKM7:TR?= NGPF[ppUSU6JRWK=
RPMI-8226 MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWWWlEPTB;MD6wNVExOiEQvF2= M3vvdXNCVkeHUh?=
SK-PN-DW M3zROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L5emlEPTB;MD6wNVEyOiEQvF2= MkPiV2FPT0WU
SF268 NGPFe|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPLTWM2OD1yLkCxNVUyKM7:TR?= NUPkT|dGW0GQR1XS
HD-MY-Z MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnviTWM2OD1yLkCxNVY{KM7:TR?= MXvTRW5ITVJ?
DOHH-2 NE\qVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEGyNFMh|ryP MXrTRW5ITVJ?
SCC-3 NUKx[YRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm2cpRKSzVyPUCuNFEzODRizszN M13Cc3NCVkeHUh?=
ST486 NWDT[pZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfVNHlEUUN3ME2wMlAyOjB2IN88US=> M3:yRnNCVkeHUh?=
NALM-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMEGyNVQh|ryP M13QSXNCVkeHUh?=
NCI-H1436 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMEGyN|Eh|ryP NIHMSG9USU6JRWK=
KE-37 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXrTWM2OD1yLkCxNlM1KM7:TR?= MlS3V2FPT0WU
RPMI-8402 NFLVPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPSdY1MUUN3ME2wMlAyOjV4IN88US=> Ml3RV2FPT0WU
RXF393 NXHCPJZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H1ZmlEPTB;MD6wNVI2PyEQvF2= NIXROWlUSU6JRWK=
KARPAS-45 Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG2TWM2OD1yLkCxNlch|ryP NHLMUWZUSU6JRWK=
HOP-62 MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjFTWM2OD1yLkCxNlc3KM7:TR?= NEnpWoFUSU6JRWK=
ES1 M{DxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHOTWM2OD1yLkCxNlg5KM7:TR?= NGW2NoVUSU6JRWK=
L-363 M3;qd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH6TWM2OD1yLkCxN|UyKM7:TR?= M3fkZ3NCVkeHUh?=
GI-1 M2Dt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLC[|FmUUN3ME2wMlAyOzd|IN88US=> NE\oepZUSU6JRWK=
CTV-1 M{LXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fsVGlEPTB;MD6wNVQ4QCEQvF2= MWjTRW5ITVJ?
TE-5 NYn0bGg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TP[GlEPTB;MD6wNVQ6PiEQvF2= NWP2WJNKW0GQR1XS
SNU-C2B NEDONZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXoOXRKSzVyPUCuNFE1QTZizszN MWLTRW5ITVJ?
K-562 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnISHhOUUN3ME2wMlAyPTF4IN88US=> M{fZb3NCVkeHUh?=
SNB75 NWD3e3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHnTWM2OD1yLkCxOVQh|ryP NWO0SHFGW0GQR1XS
MOLT-13 M4HkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDtU3hKSzVyPUCuNFE3OzdizszN MnftV2FPT0WU
LS-123 M37vWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[yPW9KSzVyPUCuNFE3PjRizszN MlGwV2FPT0WU
NCI-SNU-5 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzDTWM2OD1yLkCxO|AyKM7:TR?= MVjTRW5ITVJ?
Daudi M{P1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTaO45FUUN3ME2wMlAyPzB6IN88US=> MkTUV2FPT0WU
A253 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEG3N|gh|ryP MnfKV2FPT0WU
TGBC1TKB MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1riNmlEPTB;MD6wNVc2OiEQvF2= MmDoV2FPT0WU
SJSA-1 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEG3Olch|ryP M{nzbXNCVkeHUh?=
NCCIT MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH6[mpKSzVyPUCuNFE4PjlizszN MY\TRW5ITVJ?
NCI-H69 NVvjblFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\wTWM2OD1yLkCxO|c5KM7:TR?= NH3pTo5USU6JRWK=
SH-4 M1HkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33xVmlEPTB;MD6wNVg6PSEQvF2= MmK1V2FPT0WU
HCC1187 MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC0NZQ3UUN3ME2wMlAyQTJ2IN88US=> NX;Mb5JuW0GQR1XS
HCC1599 NV\ETIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PDVWlEPTB;MD6wNlAzKM7:TR?= NUfHOpRvW0GQR1XS
ONS-76 NFXiWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XpVWlEPTB;MD6wNlA{PiEQvF2= M4fyOHNCVkeHUh?=
KU812 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfqS45GUUN3ME2wMlAzODN7IN88US=> M4HDbXNCVkeHUh?=
ML-2 M1\6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTNN4NKSzVyPUCuNFIxPDdizszN NXzQO4N[W0GQR1XS
HCE-T MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTJTWM2OD1yLkCyNFkzKM7:TR?= MUTTRW5ITVJ?
NCI-H446 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrr[WVKSzVyPUCuNFIyOTJizszN NF\UVHlUSU6JRWK=
RPMI-6666 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\jVZhKSzVyPUCuNFIyPDlizszN M1L5O3NCVkeHUh?=
MOLT-16 M2TVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXrTWM2OD1yLkCyNVU{KM7:TR?= MoLvV2FPT0WU
JiyoyeP-2003 NXP5VFh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTDU5pKSzVyPUCuNFIyPzZizszN MWPTRW5ITVJ?
MHH-PREB-1 NGLrOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEKxPVEh|ryP NYjiSFNwW0GQR1XS
MC-CAR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnVRmVKSzVyPUCuNFI{OjZizszN MnfjV2FPT0WU
BC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnDWpJXUUN3ME2wMlAzOzR2IN88US=> MY\TRW5ITVJ?
KINGS-1 M365emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfSUWVDUUN3ME2wMlAzOzV3IN88US=> NEHvOW5USU6JRWK=
PF-382 NXX2[FV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTBTWM2OD1yLkCyN|c5KM7:TR?= NESxbI1USU6JRWK=
J-RT3-T3-5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEKzPFMh|ryP NW\ZT3NYW0GQR1XS
SF539 NI\3eGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfoTWM2OD1yLkCyOFAyKM7:TR?= MmDiV2FPT0WU
LB831-BLC MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DwbGlEPTB;MD6wNlQ5PSEQvF2= MnTzV2FPT0WU
DMS-114 NIHkTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKwTWM2OD1yLkCyOVAzKM7:TR?= MnfhV2FPT0WU
LB1047-RCC M1zubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrVTWM2OD1yLkCyOVEh|ryP NF3TT5FUSU6JRWK=
LB771-HNC NXfH[nQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEK1N|Qh|ryP MYLTRW5ITVJ?
BB65-RCC NWK2eZN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XLWWlEPTB;MD6wNlU{PCEQvF2= Mnz6V2FPT0WU
BV-173 M1vDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTvTWM2OD1yLkCyOVU1KM7:TR?= NEK3TGtUSU6JRWK=
ARH-77 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nxfmlEPTB;MD6wNlYxOSEQvF2= M{LX[HNCVkeHUh?=
IST-MEL1 MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMEK2NlMh|ryP NULlSIc2W0GQR1XS
NB1 MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEK2PFch|ryP M33G[HNCVkeHUh?=
EoL-1-cell NIHBd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMEK2PFgh|ryP M4rtdXNCVkeHUh?=
KY821 M1u2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMEK2PVch|ryP MkjxV2FPT0WU
CMK NW\qTXJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHM[phKSzVyPUCuNFI4OzRizszN NFPGUZBUSU6JRWK=
NCI-H2126 NGPlVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj2OW1KSzVyPUCuNFI4PjhizszN M33VPHNCVkeHUh?=
NCI-H526 M{CwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPQPG9bUUN3ME2wMlAzQDlzIN88US=> NXziXpBMW0GQR1XS
COLO-684 NGHPOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMEK5NFgh|ryP MXLTRW5ITVJ?
NCI-H747 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfJTWM2OD1yLkCyPVM{KM7:TR?= NHXMUm5USU6JRWK=
JAR NF7ISldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HvTGlEPTB;MD6wNlk1PiEQvF2= NIXCcHNUSU6JRWK=
MEG-01 NGj0ZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjVTWM2OD1yLkCyPVc5KM7:TR?= Mof2V2FPT0WU
MONO-MAC-6 M2ntbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETTTY9KSzVyPUCuNFMxOjNizszN NITHUHZUSU6JRWK=
IST-SL1 M3;5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HVeGlEPTB;MD6wN|A1OiEQvF2= NVPuNYQzW0GQR1XS
CPC-N NFrvfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkeyTWM2OD1yLkCzNFc6KM7:TR?= NInRcnlUSU6JRWK=
NCI-H1963 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO3TWM2OD1yLkCzNVMyKM7:TR?= NW\MVG9WW0GQR1XS
K052 NI[y[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPyc3hKSzVyPUCuNFMzPDdizszN Mnf0V2FPT0WU
KM-H2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEOzNFch|ryP NInB[JlUSU6JRWK=
TE-12 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP4TWM2OD1yLkCzN|A6KM7:TR?= M{TqZXNCVkeHUh?=
TK10 M1zDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljhTWM2OD1yLkCzN|U3KM7:TR?= M3L1[XNCVkeHUh?=
NMC-G1 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMEO0OVIh|ryP MXTTRW5ITVJ?
no-11 NFzzTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrMOpZ3UUN3ME2wMlA{PDd6IN88US=> NH2xVldUSU6JRWK=
NCI-H524 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSzdoU5UUN3ME2wMlA{PTJ7IN88US=> NHjTR4ZUSU6JRWK=
MHH-CALL-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\tcGlEPTB;MD6wN|U3OiEQvF2= M3H0T3NCVkeHUh?=
GB-1 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrJTWM2OD1yLkCzOkDPxE1? NV3yXmE{W0GQR1XS
OPM-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMEO2O|Mh|ryP MmjvV2FPT0WU
RH-1 NWrnNYNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILNRpRKSzVyPUCuNFM5OTlizszN MYLTRW5ITVJ?
NCI-H64 NGLUUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfkTWM2OD1yLkCzPFU4KM7:TR?= MWDTRW5ITVJ?
EVSA-T M2\ZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEO5NlMh|ryP M1nhXnNCVkeHUh?=
KARPAS-299 NVTucYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS1ZoRKSzVyPUCuNFM6QCEQvF2= MlO0V2FPT0WU
MZ7-mel M4nxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMESwOEDPxE1? M4CyRnNCVkeHUh?=
LB373-MEL-D MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn0bXBKSzVyPUCuNFQyODVizszN NVWzd|NrW0GQR1XS
HEL MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LNWWlEPTB;MD6wOFE1KM7:TR?= M3u1VHNCVkeHUh?=
SW872 M37zSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMESyNUDPxE1? NULSRoNnW0GQR1XS
DU-4475 NVHzPW9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTMTWM2OD1yLkC0NlQ1KM7:TR?= MnLUV2FPT0WU
IST-SL2 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fqTWlEPTB;MD6wOFI4PSEQvF2= MnHwV2FPT0WU
NCI-H82 MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4frfGlEPTB;MD6wOFMxPyEQvF2= MXXTRW5ITVJ?
LC4-1 MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zkUGlEPTB;MD6wOFM2OSEQvF2= M1nSd3NCVkeHUh?=
HDLM-2 Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMESzPVIh|ryP NXvOdosxW0GQR1XS
MMAC-SF MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDYTWM2OD1yLkC0OVM1KM7:TR?= NU\menpWW0GQR1XS
L-540 M2PJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMES2N|kh|ryP MXvTRW5ITVJ?
MZ2-MEL NEnMO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDaOYZnUUN3ME2wMlA1PzR{IN88US=> MWPTRW5ITVJ?
LU-134-A NGn0T5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvpUZFNUUN3ME2wMlA1Pzd|IN88US=> M1nBcXNCVkeHUh?=
UACC-257 NEjK[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jBWWlEPTB;MD6wOFg1QSEQvF2= Mn\nV2FPT0WU
NCI-H1581 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMES5OVMh|ryP NI[zXZRUSU6JRWK=
NB17 M4\MfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;yTWM2OD1yLkC0PVc6KM7:TR?= NHnmZ5RUSU6JRWK=
SBC-1 NIS2TI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEWwOFIh|ryP NVT2bmUzW0GQR1XS
TALL-1 NXjSOWZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEWwOFUh|ryP Ml\yV2FPT0WU
NCI-H1304 M17hTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPIWYRLUUN3ME2wMlA2OjB6IN88US=> MYLTRW5ITVJ?
NEC8 NFzXbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13MeWlEPTB;MD6wOVI5PiEQvF2= Mk\BV2FPT0WU
CAL-148 MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEW0N|kh|ryP MmHzV2FPT0WU
CGTH-W-1 MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HJTmlEPTB;MD6wOVQ1QSEQvF2= NW\2NHlsW0GQR1XS
NCI-H889 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMEW1PVIh|ryP NVWwUYh4W0GQR1XS
GR-ST M{\r[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEW2NlEh|ryP NF\4N|JUSU6JRWK=
KARPAS-422 NFjqOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoG5TWM2OD1yLkC1OlUh|ryP NEKwfXNUSU6JRWK=
RPMI-8866 NXTaW5VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEW3NVIh|ryP Ml7mV2FPT0WU
SCLC-21H NWq3WZlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTwV4U{UUN3ME2wMlA2QDh2IN88US=> NV\aVXRWW0GQR1XS
COR-L88 NEX4cI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLxTWM2OD1yLkC1PVI4KM7:TR?= NXnXeWJFW0GQR1XS
LU-139 M3jUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T4NmlEPTB;MD6wOVk5PiEQvF2= NELzV3BUSU6JRWK=
SF126 NInjeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz1[ZFKSzVyPUCuNFYyOzNizszN MmXsV2FPT0WU
NCI-H1882 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLMZ3ZKSzVyPUCuNFY1OjRizszN NIXM[VJUSU6JRWK=
EW-24 NWXFc5d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwME[0PFMh|ryP MUTTRW5ITVJ?
CP67-MEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj6cI9KSzVyPUCuNFY5OSEQvF2= M4P3O3NCVkeHUh?=
DG-75 NWG2XWp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[2N2lEPTB;MD6wOlg6QSEQvF2= MnXNV2FPT0WU
LOXIMVI MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rp[GlEPTB;MD6wO|AzQCEQvF2= NHfSRXRUSU6JRWK=
HH NE\HeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrm[YpKSzVyPUCuNFcyPTdizszN MmjLV2FPT0WU
K5 M2LUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHKUVJKSzVyPUCuNFczOjZizszN NIP4c5pUSU6JRWK=
EC-GI-10 MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEeyOVch|ryP M4jHXXNCVkeHUh?=
SK-N-DZ NX;KeWR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPSd2JKSzVyPUCuNFc{ODdizszN MnLkV2FPT0WU
A3-KAW NWDCNWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEezOVEh|ryP NF7MNIpUSU6JRWK=
MLMA NYLaeIdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LlXGlEPTB;MD6wO|Q3PSEQvF2= MYXTRW5ITVJ?
LB996-RCC M4jveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi2dlh6UUN3ME2wMlA4PzB5IN88US=> MVPTRW5ITVJ?
OS-RC-2 M1flSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MornTWM2OD1yLkC3O|Q5KM7:TR?= MX7TRW5ITVJ?
CTB-1 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvSOWtKSzVyPUCuNFc5OSEQvF2= MUjTRW5ITVJ?
IST-MES1 NXTKPJlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnroTWM2OD1yLkC3PVEzKM7:TR?= MlvoV2FPT0WU
LS-1034 M3fjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ENldKSzVyPUCuNFgxOzVizszN MU\TRW5ITVJ?
HT MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rxUWlEPTB;MD6wPFA5PiEQvF2= NYO5TZFJW0GQR1XS
NCI-H2141 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj0TWM2OD1yLkC4NUDPxE1? MofyV2FPT0WU
LB2518-MEL M2SxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPjRllsUUN3ME2wMlA5OTRzIN88US=> MUDTRW5ITVJ?
GI-ME-N M1;zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEi0OVIh|ryP M2ruZ3NCVkeHUh?=
TGW NFvVVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\RT2lEPTB;MD6wPFYxPyEQvF2= MVrTRW5ITVJ?
SK-NEP-1 M1n6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEi2OFEh|ryP NFPrVZZUSU6JRWK=
NOMO-1 M4DE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzYTWM2OD1yLkC5Nlc2KM7:TR?= NVm0Vo0{W0GQR1XS
ES6 M3HXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vycWlEPTB;MD6wPVU5QSEQvF2= NVnzfmtYW0GQR1XS
NCI-H209 M1;3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfnN2R3UUN3ME2wMlA6Pzh4IN88US=> MnrGV2FPT0WU
GAK M3vCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV75ZWx4UUN3ME2wMlExOTZizszN NXu0d4NwW0GQR1XS
BC-1 M3vFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHwTWM2OD1yLkGwN|YyKM7:TR?= M2XJXHNCVkeHUh?=
KLE NWGzZoNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly4TWM2OD1yLkGwOFQ{KM7:TR?= NWXlUVZtW0GQR1XS
EW-3 NHP1V5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1mxWGlEPTB;MD6xNFk5KM7:TR?= MX;TRW5ITVJ?
NKM-1 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrMfZQ3UUN3ME2wMlEyOSEQvF2= NIHJWIdUSU6JRWK=
D-336MG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLzTWM2OD1yLkGxNlQ1KM7:TR?= MnTBV2FPT0WU
NB69 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj4fo5KSzVyPUCuNVE{ODFizszN MlvWV2FPT0WU
D-263MG NIn2SVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMUG3NVIh|ryP MUPTRW5ITVJ?
KP-N-YS MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37ob2lEPTB;MD6xNlI6OSEQvF2= MkjEV2FPT0WU
NCI-H1155 NVvyXpN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDMTWM2OD1yLkGyOVU5KM7:TR?= MmjQV2FPT0WU
BOKU MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMUK1O|kh|ryP Mke2V2FPT0WU
LAMA-84 MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6xTWM2OD1yLkGyPVkh|ryP M4rsVnNCVkeHUh?=
Raji NXOy[JpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j5dWlEPTB;MD6xN|EyPyEQvF2= NEHPU5RUSU6JRWK=
LU-65 M1rOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ezRWlEPTB;MD6xN|MxPyEQvF2= MYnTRW5ITVJ?
NCI-H187 M2PwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjLW|k1UUN3ME2wMlE{QTJ2IN88US=> MlrQV2FPT0WU
GCIY NWDFdpNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MornTWM2OD1yLkG0PVAyKM7:TR?= NULkU|NVW0GQR1XS
NCI-H2107 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rtUWlEPTB;MD6xOVA5KM7:TR?= NGH0bIVUSU6JRWK=
NCI-H1522 NUH5S45PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XQU2lEPTB;MD6xOVI3PiEQvF2= NYrlZXhXW0GQR1XS
NB6 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj2fJBKSzVyPUCuNVU3OjNizszN M2\6OHNCVkeHUh?=
EM-2 M1:4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMUW3NFYh|ryP MWPTRW5ITVJ?
HCC2218 Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rzcmlEPTB;MD6xOVk5KM7:TR?= M{HnTHNCVkeHUh?=
NCI-H748 NX:xfWkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXtPYZKSzVyPUCuNVY{PzZizszN MV3TRW5ITVJ?
MS-1 NVW4O|ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rPVmlEPTB;MD6xOlU{PyEQvF2= NXPYfmtPW0GQR1XS
NB5 M3TV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPa[INKSzVyPUCuNVY2QTdizszN M1;FVHNCVkeHUh?=
OMC-1 M3LY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:2SYZKSzVyPUCuNVY3QDhizszN M{jkfnNCVkeHUh?=
NCI-H345 NVLic3h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGwOoZIUUN3ME2wMlE3QTJ6IN88US=> M2j0N3NCVkeHUh?=
L-428 M130RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXOe3hKSzVyPUCuNVY6PDVizszN NFzNZ3JUSU6JRWK=
SCH MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj4cG1KSzVyPUCuNVg3QDVizszN MXTTRW5ITVJ?
NCI-H1417 NIToS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4V2lEPTB;MD6xPVIzPyEQvF2= MX\TRW5ITVJ?
COLO-320-HSR M3nacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jXWWlEPTB;MD6xPVU{OiEQvF2= M2n5NHNCVkeHUh?=
BT-474 NIXGTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LkVGlEPTB;MD6yNFg6OiEQvF2= MmHDV2FPT0WU
GDM-1 M3fLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfTUmNKSzVyPUCuNlE6PzFizszN NF7senhUSU6JRWK=
NCI-H2196 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMkKyN|Uh|ryP M1\mWnNCVkeHUh?=
KP-N-RT-BM-1 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j5cmlEPTB;MD6yNlM1QSEQvF2= M2jWcXNCVkeHUh?=
KNS-81-FD NXfB[Gw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXZT2xLUUN3ME2wMlIzQTV6IN88US=> MUfTRW5ITVJ?
COLO-668 NFjQNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfFTWM2OD1yLkKzOlc2KM7:TR?= NE\Fb|JUSU6JRWK=
C2BBe1 NI[2d4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\lTWM2OD1yLkK2O|Q4KM7:TR?= MX7TRW5ITVJ?
Ramos-2G6-4C10 NIG5dHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTEOpY1UUN3ME2wMlI3QTV2IN88US=> MXHTRW5ITVJ?
CAS-1 NUD6PVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP3OVBwUUN3ME2wMlI4ODl4IN88US=> MlTjV2FPT0WU
GOTO NV[1SWlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\PbWlEPTB;MD6yO|g6PCEQvF2= NF3SV5FUSU6JRWK=
LP-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\5UGlEPTB;MD6yPFA2PyEQvF2= NVOxNIZwW0GQR1XS
NCI-SNU-1 NUDycZJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnUTWM2OD1yLkK5OFIzKM7:TR?= MnX0V2FPT0WU
EB-3 NX;qTlVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMkm5O|kh|ryP M125THNCVkeHUh?=
MHH-NB-11 M3:xXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwM{C0NFIh|ryP MYPTRW5ITVJ?
SK-N-FI NGHqNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXO[GZKSzVyPUCuN|E3QTJizszN MnzEV2FPT0WU
HCC2157 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHJUppKSzVyPUCuN|M6OTNizszN M{nlR3NCVkeHUh?=
SIMA NFfRXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1faTWlEPTB;MD6zOFU5OSEQvF2= NXjNNXRHW0GQR1XS
MDA-MB-134-VI MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f2WmlEPTB;MD6zOlkzQCEQvF2= MYrTRW5ITVJ?
NCI-H1694 Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq1e4RKSzVyPUCuN|ch|ryP M4rs[XNCVkeHUh?=
EHEB NFLGfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwM{mwPFUh|ryP NIfHVFlUSU6JRWK=
U-266 M{mzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrwRmNKSzVyPUCuN|k5PDZizszN MVLTRW5ITVJ?
LC-1F MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uzVmlEPTB;MD60N|c3PSEQvF2= MljDV2FPT0WU
SHP-77 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET6NFJKSzVyPUCuOFc5PTVizszN MorPV2FPT0WU
LS-513 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TueWlEPTB;MD60PVMxPyEQvF2= NIrZNG5USU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
体内研究

Paclitaxel单独处理 BC-V 和 BC-ER肿瘤的抑制定额分别为49.78 和 51.23%。20 mg/kg Paclitaxel处理6个周期,显著降低Ki-67阳性细胞百分比,BC-V肿瘤中降到20.4%,BC-ER 肿瘤中降到25.1%。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: 细胞,包括人类新生儿皮肤微血管内皮细胞(HMVECs), 人脐静脉内皮细胞(HUVECs), 人脐动脉内皮细胞 (HUAVECs), 正常人类星形胶质细胞(NHAs), 正常人体皮肤成纤维细胞(NHDFs), 正常人表皮角质形成细胞(NHEKs), 人类乳腺上皮细胞(HMEpCs), 人前列腺上皮细胞(PrEpCs) 和人脐动脉平滑肌细胞(UASMCs)
  • Concentrations: 0.1 pM-100 pM
  • Incubation Time: 72 小时
  • Method:

    培养细胞,包括人类新生儿皮肤微血管内皮细胞(HMVECs), 人脐静脉内皮细胞(HUVECs), 人脐动脉内皮细胞 (HUAVECs), 正常人类星形胶质细胞(NHAs), 正常人体皮肤成纤维细胞(NHDFs), 正常人表皮角质形成细胞(NHEKs), 人类乳腺上皮细胞(HMEpCs), 人前列腺上皮细胞(PrEpCs) 和人脐动脉平滑肌细胞(UASMCs)。在96孔板中使用6和12通道的细胞进行增殖。细胞按每孔3000–5000个细胞接种,然后粘附4小时。Paclitaxel在培养基中稀释,然后按一式四份加到孔中,细胞温育3天,然后加入MTS 试剂,然后定量测量每孔中的活细胞。


    (Only for Reference)
动物实验:

[4]

- 合并
  • Animal Models: 携带BC-V 和 BC-ER肿瘤的雌性20-22 g 纯和裸鼠
  • Dosages: 20 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Water Insoluble
Ethanol '18 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
6mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 853.91
化学式

C47H51NO14

CAS号 33069-62-4
储存条件 粉状
溶于溶剂
别名 NSC 125973, PTX, Taxol, Onxal

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04338399 Not yet recruiting Drug: Buparlisib & Paclitaxel Head and Neck Cancer Adlai Nortye Biopharma Co. Ltd. July 31 2020 Phase 3
NCT04251169 Not yet recruiting Drug: Pembrolizumab|Drug: Paclitaxel Metastatic Breast Cancer SOLTI Breast Cancer Research Group|Merck Sharp & Dohme Corp. July 15 2020 Phase 2
NCT04252768 Not yet recruiting Drug: Eftilagimod Alpha|Drug: Paclitaxel Metastatic Breast Cancer Immutep S.A. June 2020 Phase 1
NCT04374630 Not yet recruiting Drug: Paclitaxel|Drug: Afuresertib Platinum-resistant Ovarian Cancer Laekna Limited June 9 2020 Phase 2
NCT04354961 Not yet recruiting Drug: Almonertinib|Drug: Paclitaxel and carboplatin Pulmonary Adenosquamous Carcinoma Fujian Cancer Hospital|Jiangsu Hansoh Pharmaceutical Co. Ltd. June 2020 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 问题 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Tags: 购买Paclitaxel | Paclitaxel供应商 | 采购Paclitaxel | Paclitaxel价格 | Paclitaxel生产 | 订购Paclitaxel | Paclitaxel代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID